Li Shu-Ying, Li Ke, Qin Xue-Mei, Li Xian-Rong, DU Yu-Guang
Modern Research Center for Traditional Chinese Medicine,Shanxi University Taiyuan 030006,China College of Chemistry and Chemical Engineering,Shanxi University Taiyuan 030006,China Key Laboratory of Effective Substances Research and Utilization in Traditional Chinese Medicine of Shanxi Province Taiyuan 030006,China.
Modern Research Center for Traditional Chinese Medicine,Shanxi University Taiyuan 030006,China Key Laboratory of Effective Substances Research and Utilization in Traditional Chinese Medicine of Shanxi Province Taiyuan 030006,China.
Zhongguo Zhong Yao Za Zhi. 2019 Jul;44(13):2736-2741. doi: 10.19540/j.cnki.cjcmm.20190321.303.
Astragali Radix( AR) polysaccharide for injection( Guoyao Zhunzi Z20040086) is a traditional Chinese medicine for intravenous powder injection developed by Shanxi Academy of Traditional Chinese Medicine in early 1990 s by taking advantage of AR resources in Shanxi province. The effective parts of AR polysaccharides were obtained by advanced technology. The hemogram of patients with radiotherapy and chemotherapy showed alleviations in clinic. However,due to the technical bottleneck in separation of the complex polysaccharides mixture and the difficulties in accurate measurement of the polysaccharide structures,the pharmacodynamic mechanism of the drug remained unclear,and the side effect was hard to control. In recent years,the theoretical studies for polysaccharide receptors have indicated that when polysaccharides bound to protein receptors,only the oligosaccharide fragments of the polysaccharide molecule bound to the receptors,and one or more active sites of oligosaccharide fragments may existed in the polysaccharide molecule.Therefore,the active center of polysaccharides can be studied based on the level of oligosaccharides through degradation of the polysaccharides,which provided a new strategy for breaking through the bottleneck in polysaccharide structure determination. Therefore,this paper reviews the current status of studies for AR polysaccharides for injection,the polysaccharide receptors theory and successful cases,in order to propose the secondary development ideas of AR polysaccharides for injection. The study results will lay a material foundation for the development of new drugs of polysaccharides from traditional Chinese medicine,and provide a basis for the resolution of international difficulties in quality control of polysaccharide drugs and molecular models,so as to further study of glycobiology,and enrich the polysaccharide receptors theory.
注射用黄芪多糖(国药准字Z20040086)是山西省中医药研究院于20世纪90年代初利用山西省黄芪资源研发的一种用于静脉注射的中药粉针剂。采用先进技术获得黄芪多糖的有效部位。放疗和化疗患者的血常规在临床上显示有所改善。然而,由于复杂多糖混合物分离的技术瓶颈以及多糖结构精确测定的困难,该药物的药效学机制仍不清楚,且副作用难以控制。近年来,多糖受体的理论研究表明,当多糖与蛋白质受体结合时,只有多糖分子的寡糖片段与受体结合,且多糖分子中可能存在一个或多个寡糖片段的活性位点。因此,可以通过多糖降解从寡糖水平研究多糖的活性中心,这为突破多糖结构测定的瓶颈提供了新策略。因此,本文综述了注射用黄芪多糖的研究现状、多糖受体理论及成功案例,以期提出注射用黄芪多糖的二次开发思路。研究结果将为中药多糖新药开发奠定物质基础,为解决多糖药物质量控制及分子模型的国际难题提供依据,从而进一步开展糖生物学研究,丰富多糖受体理论。